SCHEMBL10141758

SCHEMBL10141758

COc1ccc(CNC(C)=O)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.65
ALDH1A1 P00352 2/20 0.59
TAS1R3 Q7RTX0 2/20 0.59
TAS1R1 Q7RTX1 2/20 0.59
TSHR P16473 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
GAA P10253 1/20 0.58
PKM P14618 1/20 0.58
HPGD P15428 1/20 0.58
HTT P42858 1/20 0.58
MTNR1A P48039 1/20 0.57
MTNR1B P49286 1/20 0.57
POLB P06746 1/20 0.55
CNR1 P21554 1/20 0.54
CNR2 P34972 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30698721 0.89 APLNR (0.59) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL18415441 0.89 TAS1R3 (0.67) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL18971053 0.88 TAS1R3 (0.57) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL30849698 0.87 MTNR1A (0.69) ALDH1A1GAAPKMHPGDHTT
SCHEMBL2261220 0.87 APLNR (0.65) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL5570100 0.87 APLNR (0.65) APLNRMTNR1AMTNR1B
SCHEMBL29209631 0.86 APLNR (0.59) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL3361891 0.86 APLNR (0.63) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL14521439 0.84 APLNR (0.61) APLNRALDH1A1TAS1R3TAS1R1TSHR
SCHEMBL4259873 0.84 APLNR (0.61) APLNRALDH1A1TAS1R3TAS1R1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 US disclosed
US-9181265-B2 Substituted 2,3-dihydro-1H-benzo[a]pyrano[2,3-c]phenazines as anti-angiogenic and anti-cancer agents UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2015-11-10 US disclosed
CN-104781256-A 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel HOFFMANN LA ROCHE 2015-07-15 CN disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 US disclosed
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES UNIVERSITE LIBRE DE BRUXELLES (BE) 2013-10-31 US disclosed
US-8569267-B2 Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain JANSSEN PHARMACEUTICA, NV (BE) 2013-10-29 US disclosed
US-8569267-B2 Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain JANSSEN PHARMACEUTICA, NV (BE) 2013-10-29 US disclosed
WO-2012085222-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USE UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) 2012-06-28 WO disclosed
US-7538241-B2 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-05-26 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain JANSSEN PHARMACEUTICA, NV (BE) 2008-10-23 US disclosed
US-20070155813-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-07-05 US disclosed
US-20070155813-A1 Hsp90 family protein inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-07-05 US disclosed
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma PHARMACIA CORPORATION 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262076-A1 Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain HTR2C, HTR2A, HTR5A APLNR 298/4885ALDH1A1 848/4885TAS1R3 271/4885
US-20070155813-A1 Hsp90 family protein inhibitors HSP90AB1, HEATR1, HSP90AB2P APLNR 4148/4885ALDH1A1 3520/4885TAS1R3 1883/4885
US-20070078146-A1 Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma MAPK1, MAPK3, MAPK4 APLNR 4127/4885ALDH1A1 1079/4885TAS1R3 3547/4885
US-20130289030-A1 NOVEL PHENAZINE DERIVATIVES AND THEIR USES VEGFA, KDR, FLT4 APLNR 362/4885ALDH1A1 671/4885TAS1R3 4234/4885
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 APLNR 2167/4885ALDH1A1 4807/4885TAS1R3 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.